Synageva BioPharma Lands $25,000,000 New Funding Round

  • Feed Type
  • Date
  • Company Name
    Synageva BioPharma
  • Mailing Address
    128 Spring St. Lexington, MA 02421
  • Company Description
    Synageva BioPharma’s goal is to improve the lives of patients with rare and ultra rare diseases (diseases that affect less than 200,000 and 10,000 patients respectively) by providing access to breakthrough protein therapeutics. Our team has played pivotal roles in developing and/or commercializing the majority of the ultra orphan therapies that have been marketed to date. We are combining this expertise with the best new approaches in translational medicine to develop our pipeline of rare disease therapies for serious and life threatening conditions.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    In addition to initiating the global clinical studies for SBC-102, Synageva continues to expand the network of physicians and medical professionals that will be instrumental in developing this program and the company’s other rare disease therapeutic candidates.
  • M&A Terms
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Baker Brothers Investments
  • Venture Investor

Trending on Xconomy